NATICK, Mass., May 22, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the upcoming presentation of clinical and preclinical data highlighting its novel first-in-class drug candidates directed against nuclear transport targets for the treatment of cancer at the 19th Congress of the European Hematology Association (EHA) being held June 12-15, 2014 in Milan, Italy.